XOMA to Webcast Analyst and Investor Event 'Interleukin-1 Blockers: Unlocking Their Potential in Diabetes and Beyond' On September 25
22 sept. 2008 08h05 HE
|
XOMA Corporation
BERKELEY, Calif., Sept. 22, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today that the company will host a live web...
XOMA to Present At the UBS Global Life Sciences Conference On September 22
16 sept. 2008 16h35 HE
|
XOMA Corporation
BERKELEY, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today that Steven Engle, Chairman and Chief...
New Programs Added in Antibody Collaboration Between XOMA and Takeda
15 sept. 2008 16h35 HE
|
XOMA Corporation
BERKELEY, Calif., Sept. 15, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today the initiation of new therapeutic...
Texas A&M University System and XOMA Sign Memorandum of Understanding
10 sept. 2008 16h35 HE
|
XOMA Corporation
COLLEGE STATION, Texas and BERKELEY, Calif., Sept. 10, 2008 (GLOBE NEWSWIRE) -- The Texas A&M University System and XOMA, Ltd (Nasdaq:XOMA), a leader in the discovery and development of...
XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical Trials
09 sept. 2008 13h57 HE
|
XOMA Corporation
BERKELEY, Calif., Sept. 9, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it was awarded a $65 million multiple year contract from the National Institute of Allergy and...
XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells
08 sept. 2008 05h00 HE
|
XOMA Corporation
ROME, Sept. 8, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced interim data from two Phase 1 clinical studies of XOMA 052, an antibody drug candidate with an ultra high binding affinity of...
XOMA Reports Second Quarter 2008 Financial Results
07 août 2008 16h02 HE
|
XOMA Corporation
BERKELEY, Calif., Aug. 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its results for the quarter ended June...
XOMA to Announce Second Quarter 2008 Financial Results and Host Conference Call On Thursday, August 7
04 août 2008 07h00 HE
|
XOMA Corporation
BERKELEY, Calif., Aug. 4, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the Company will host a conference call...
XOMA Announces Departure of CFO
28 juil. 2008 08h30 HE
|
XOMA Corporation
BERKELEY, Calif., July 28, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that J. David Boyle II, XOMA's Vice President of Finance and Chief Financial Officer, has resigned from the...
XOMA Begins Phase 2a Clinical Trial to Evaluate XOMA 629 Topical Gel as a Treatment for the Common Skin Disease, Impetigo
24 juil. 2008 16h41 HE
|
XOMA Corporation
BERKELEY, Calif., July 24, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced the start of its Phase 2a clinical...